U.S. Professional Services Stock News

Investors may be wondering whether Capri Holdings shares still offer value after a turbulent few years, or if most of the opportunity is already reflected in the current price. The stock last closed at US$19.88, with returns of 10.7% over 7 days, 7.0% over 30 days, an 18.5% decline year to date and a 35.7% gain over the past year, while 3 and 5 year returns stand at 55.3% and 63.1% declines respectively. Recent price moves have come as investors reassess the brand portfolio and the broader...

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...

If you are wondering whether Futu Holdings at US$154.50 is still reasonably priced after a strong run, the next sections will focus squarely on what the current share price might imply about value. The stock has returned 10.2% over the past week and 9.5% over the past month, with a 92.2% return over the last year but a 13.4% decline year to date and a 230.6% return over three years and 3.3% over five years. Recent coverage has highlighted Futu Holdings as a prominent online brokerage play...

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...

Freshworks (NasdaqGS:FRSH) appointed Kuntal Vahalia as Senior Vice President, Partnership Channel. Vahalia will lead the company’s global partner strategy with a focus on the partner channel. The role includes supporting Freshworks’ efforts to move further upmarket and deepen ties with global system integrators. For investors tracking SaaS platforms, Freshworks operates in the customer and employee experience software space, where partner ecosystems often influence how quickly products...

Five Below (NasdaqGS:FIVE) reported strong quarterly results, with revenue and earnings exceeding analyst expectations. The company opened a new store in Corbin, Kentucky, adding to its growing brick and mortar footprint. Management, led by CEO Winnie Park, highlighted ongoing progress on key business initiatives alongside the latest store launch. Five Below enters this update cycle with its shares at $217.37 and a very large 1 year return of 259.5%. The company has also recorded a 12.4%...

If you are wondering whether Winmark at around US$444 per share offers good value or if you might be arriving late, this piece lays out the key facts so you can judge the price for yourself. The stock has recently moved 3.2% over the last 7 days, with a 1 year return of 37.5% and 10.6% year to date. The 30 day return sits at a 1.2% decline and the 3 and 5 year returns are 46.1% and 163.2% respectively. Recent attention around Winmark has focused on its position in the Specialty Retail space...

If you are wondering whether Ventas at around US$84.96 is offering fair value or a stretched price, you are in the right place for a clear valuation breakdown. The stock has returned 2.0% over the last week, 9.9% year to date and 32.0% over the past year. Over the last 30 days it has declined 1.8%, which may have shifted some investors' sense of risk and opportunity. Recent coverage has focused on Ventas in the context of its role as a health care focused REIT, with attention on how its...

Anbio Biotechnology, NasdaqGM:NNNN, is expanding beyond COVID-19 diagnostics into a broader test portfolio. The company is rolling out new rapid immunoassay and PCR platforms across human health, veterinary, and multi-disease applications. This move reflects a business model shift toward more diversified diagnostic revenues and reduced reliance on legacy COVID-19 products. For you as an investor, this repositioning matters because Anbio Biotechnology is moving from a single product focus...

EQT (NYSE:EQT) agreed to purchase an additional 1 million metric tons of LNG per year from Commonwealth LNG, bringing its total contracted volume to 2 million tons annually. Glencore now has long-term commitments for 3 million tons of LNG per year from Commonwealth LNG. With these contracts, Commonwealth LNG reports that 8 of its planned 9.5 million tons of annual capacity is now under long-term agreements. EQT is a major U.S. natural gas producer, and this latest LNG deal increases its...

Wondering whether Perrigo's current share price makes sense or if the market has mispriced it? This article walks through the key valuation clues that can help you frame that question. The stock has seen a 0.1% move over the last 7 days and a 16.8% return over the past month, set against a much tougher picture with a 21.8% decline year to date and a 52.9% fall over the last year, as well as 65.7% and 68.3% declines over 3 and 5 years respectively. Recent attention on Perrigo has focused less...

ASP Isotopes (ASPI) has just put out its FY 2025 numbers, with Q4 revenue of about US$16.7 million and a Q4 basic EPS loss of US$0.76. Trailing twelve month revenue sits at roughly US$23.8 million against a TTM basic EPS loss of US$2.11. The company has seen quarterly revenue move from around US$1.2 million in Q4 FY 2024 to US$16.7 million in Q4 FY 2025, while trailing twelve month revenue shifted from about US$4.1 million to US$23.8 million over the same window. Investors will now be...

Unity Software (NYSE:U) is pivoting its ads business toward AI, positioning the Vector ad platform as its primary growth driver. The company is sunsetting the legacy ironSource Ads Network and is exploring a sale of its Supersonic publishing unit. Management expects Vector to reach a billion dollar annual run rate, with recent trends supporting upgrades to company guidance. Unity Software enters this shift with a share price of $21.62 and a mixed return profile, including a 51.1% decline...

State Street (NYSE:STT) has filed to launch a Nasdaq 100 Index ETF, entering a segment where Invesco has been a long-standing player. The firm is extending its relationship with Thornburg Investment Management to service new ETF share classes across Thornburg funds. Shareholders have introduced a proposal seeking a policy for an independent board chair at State Street. For investors watching the ETF space, these moves put State Street, a major global custody bank and asset manager, closer...

Adlai Nortye (NasdaqGM:ANL) has posted its FY 2025 first half results with total revenue of effectively US$0, a basic EPS loss of US$0.57 and net income loss of US$18.34 million, keeping the story firmly about cash burn and margins rather than top line scale. The company has seen recent periods marked by similarly low reported revenue, with basic EPS losses of US$0.64 and US$1.06 and net income losses of US$24.26 million and US$27.61 million across the two halves of FY 2024. As a result,...

In April 2026, Immunovant reported that two Phase 3 GO studies of its FcRn inhibitor batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the pre-specified primary endpoint of ≥2mm proptosis response at Week 24, though safety findings remained consistent and no new signals emerged. The data suggested stronger proptosis improvements during the initial high-dose period and thyroid hormone normalization in hyperthyroid patients similar to prior Graves’ disease...

Core & Main’s recent Q4 earnings report showed a 6.9% year-on-year revenue decline and slight misses on both quarterly revenue and full-year EBITDA guidance compared with analyst expectations. Despite these softer figures, investor reaction suggests the market may have been braced for weaker results or took confidence from management’s commentary and forward-looking remarks. We’ll now explore how the softer Q4 revenue and guidance miss may reshape Core & Main’s broader investment narrative...

Medline (NasdaqGS:MDLN) has received an FDA warning letter citing manufacturing deficiencies in its angiographic syringe production. The letter, the first major regulatory challenge since Medline went public, focuses on quality and compliance issues with potential patient safety implications. The FDA action requires Medline to address identified problems and document corrective steps before the matter can be closed. For investors following Medline at a share price of $45.6, this FDA warning...

Ulta Beauty (NasdaqGS:ULTA) has completed its acquisition of UK beauty retailer Space NK, expanding its presence outside the US. The company is broadening in store e commerce fulfillment and order management capabilities across its footprint. Ulta is rolling out exclusive US access to Messi Fragrances, including Messi Elixir Parfum Intense, and expanding brands such as Virtue Labs in hair and wellness. Ulta Beauty, a large specialty beauty retailer in the US, is pushing more firmly into...

Wondering whether Nutanix at around US$34.41 is a bargain or a value trap? This article breaks down what that price could imply for you. The stock has seen sharp swings recently, with a 16.3% decline over the last 7 days, a 10.0% decline over 30 days, a 32.0% decline year to date and a 42.0% decline over the last year, even though 3 year and 5 year returns sit at 34.9% and 25.9% respectively. Recent coverage has focused on Nutanix as a key player in cloud infrastructure software and as a...

In recent months, ClearBridge Investments added The Ensign Group, Inc. to its Small Cap Growth Strategy after the company delivered strong fourth-quarter 2025 earnings with margins and adjusted EPS ahead of forecasts despite slightly softer revenue. This combination of new institutional interest and consistent growth through acquisitions in a still-fragmented skilled nursing market highlights how Ensign’s consolidation model remains central to its business story, even as return on invested...

In early April 2026, Fortune Brands Innovations, Inc. disclosed disappointing Q4 results with full-year EPS guidance below analyst expectations, while also filing proxy materials urging shareholders to vote against a proposal to require annual election of all directors at the upcoming May 5, 2026 annual meeting. An interesting twist is that, even as the company encourages investors to reject a shareholder declassification proposal, it has already obtained approval to amend its certificate...

BARDA Contract Puts NexoBrid Partnership in Focus for Vericel (VCEL) Vericel (VCEL), the exclusive distributor of NexoBrid in North America, is back on investor radar after a ten-year BARDA contract valued at up to US$197 million, tied to NexoBrid procurement and development. See our latest analysis for Vericel. The BARDA news lands after a mixed run for Vericel, with a 30 day share price return of 2.49% contrasting with a 90 day share price return decline of 12.6% and a 1 year total...